Table 3 Summary of the diagnostic meta-analysis in the whole population
Marker | No. of study | Sensitivity, % (95% CI) | Specificity, % (95% CI) | DOR (95% CI) | Relative sensitivity (95% CI) | Relative specificity (95% CI) | Relative DOR (95% CI) |
|---|---|---|---|---|---|---|---|
NGAL | 35 | 76.8 (72.3–80.8) | 80.7 (77.1–83.8) | 13.8 (10.2–18.8) | Reference | Reference | Reference |
IL-18 | 12 | 67.6 (60.4–74.0) | 80.0 (76.1–83.5) | 8.4 (5.7–12.1) | 0.88 (0.80–0.96)* | 0.99 (0.97–1.02) | 0.60 (0.44–0.82)* |
IL-18/Cr | 3 | 71.9 (63.3–79.1) | 80.6 (75.0–85.3) | 10.6 (6.4–17.6) | 0.94 (0.84–1.04) | 1.00 (0.95–1.05) | 0.77 (0.48–1.23) |
KIM-1 | 14 | 76.3 (70.4–81.4) | 79.4 (75.2–83.1) | 12.4 (8.5–18.1) | 0.99 (0.93–1.06) | 0.98 (0.96–1.01) | 0.90 (0.65–1.23) |
KIM-1/Cr | 6 | 69.9 (60.1–78.1) | 83.8 (78.8–87.7) | 12.0 (7.0–20.3) | 0.91 (0.80–1.03) | 1.04 (0.99–1.09) | 0.86 (0.52–1.43) |
L-FABP | 10 | 69.8 (62.0–76.5) | 81.0 (77.0–84.4) | 9.8 (6.5–14.8) | 0.91 (0.83–0.998)* | 1.00 (0.98–1.03) | 0.71 (0.50–1.01) |
L-FABP/Cr | 8 | 81.8 (74.0–87.7) | 69.6 (58.5–78.7) | 10.3 (5.4–19.7) | 1.07 (0.97–1.17) | 0.86 (0.75–0.99)* | 0.74 (0.38–1.44) |
NGAL/Cr | 9 | 71.6 (63.5–78.5) | 86.5 (82.5–89.7) | 16.2 (10.1–25.9) | 0.93 (0.84–1.03) | 1.07 (1.03–1.11)* | 1.17 (0.75–1.82) |
Serum NGAL | 40 | 76.3 (71.6–80.4) | 79.7 (75.9–83.0) | 12.6 (9.3–17.3) | 0.99 (0.94–1.05) | 0.99 (0.96–1.01) | 0.91 (0.69–1.21) |
TIMP-2 × IGFBP-7: custom | 6 | 86.3 (74.8–93.0) | 57.6 (43.1–70.9) | 8.5 (3.4–21.4) | 1.12 (0.999–1.26) | 0.71 (0.56–0.92)* | 0.62 (0.23–1.63) |
TIMP-2 × IGFBP-7: 0.3 | 17 | 68.0 (58.1–76.4) | 73.5 (64.1–81.1) | 5.9 (3.3–10.4) | 0.88 (0.76–1.02) | 0.91 (0.80–1.03) | 0.42 (0.22–0.81)* |
TIMP-2 × IGFBP-7: 2 | 11 | 18.5 (12.4–26.8) | 97.3 (95.7–98.4) | 8.3 (4.3–16.1) | 0.24 (0.16–0.36)* | 1.21 (1.15–1.26)* | 0.60 (0.29–1.24) |